|
業務類別
|
Biotechnology |
|
業務概覽
|
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs. |
| 公司地址
| 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 443-6209 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ideayabio.com |
| 員工數量
| 145 |
| Dr. Darrin M. Beaupre, M.D. |
Chief Medical Officer |
美元 526.50K |
29/04/2026 |
| Mr. Douglas B. Snyder |
Chief Legal Officer |
-- |
29/04/2026 |
| Mr. Joshua Bleharski, PhD |
Chief Financial Officer |
美元 333.33K |
29/04/2026 |
| Mr. Yujiro S. Hata |
Director, President and Chief Executive Officer |
美元 700.00K |
29/04/2026 |
| Dr. Michael Anthony White, PhD |
Chief Scientific Officer |
美元 519.00K |
29/04/2026 |
| Mr. Andres Ruiz Briseno |
Chief Accounting Officer |
美元 417.00K |
29/04/2026 |
| Mr. Stuart Dorman |
Chief Commercial Officer |
-- |
29/04/2026 |
|
|
| Dr. Terry Rosen, PhD |
Chairman of the Board |
29/04/2026 |
| Ms. Wendy L. Yarno, M.B.A. |
Independent Director |
29/04/2026 |
| Dr. Jeffrey Stein, PhD |
Independent Director |
29/04/2026 |
| Dr. Catherine J. Mackey, PhD |
Independent Director |
29/04/2026 |
| Mr. Yujiro S. Hata |
Director, President and Chief Executive Officer |
29/04/2026 |
| Mr. Scott William Morrison |
Independent Director |
29/04/2026 |
| Mr. Malcolm Garret Hampton, PhD |
Independent Director |
29/04/2026 |
|
|
|
|
